nach oben

Medical Oncology

Erschienen in:

01.01.2024 | Original Paper

USP10 promotes migration and cisplatin resistance in esophageal squamous cell carcinoma cells

verfasst von: Sicong Hou, Tiantian Zhao, Bin Deng, Caimin Li, Wenqian Li, Haifeng Huang, Qinglei Hang

Erschienen in: Medical Oncology | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Cisplatin-based chemotherapy is the main treatment option for advanced or metastatic esophageal squamous cell carcinoma (ESCC). However, most ESCC patients develop drug resistance within 2 years after receiving cisplatin chemotherapy. Ubiquitin-specific protease 10 (USP10) is abnormally expressed in a variety of cancers, but the mechanistic roles of USP10 in ESCC are still obscure. Here, the effects of USP10 on the migration and cisplatin resistance of ESCC in vivo and in vitro and the underlying mechanisms have been investigated by bioinformatics analysis, RT-PCR, western blotting, immunoprecipitation, immunohistochemistry, cell migration and MTS cell proliferation assays, deubiquitination assay, and mouse tail vein injection model. USP10 was significantly up-regulated in ESCC tissues compared with adjacent normal tissues in both public databases and clinical samples and was closely associated with overall survival. Subsequent results revealed that USP10 contributed to the migration and cisplatin resistance of ESCC cells, while knocking down USP10 in cisplatin-resistant cells exhibited opposite effects in vitro and in vivo. Further Co-IP experiments showed that integrin β1 and YAP might be targets for USP10 deubiquitination. Moreover, deficiency of USP10 significantly inhibited the migrative and chemo-resistant abilities of ESCC cells, which could be majorly reversed by integrin β1 or YAP reconstitution. Altogether, USP10 was required for migration and cisplatin resistance in ESCC through deubiquinating and stabilizing integrin β1/YAP, highlighting that inhibition of USP10 may be a potential therapeutic strategy for ESCC.

Abnet CC, Arnold M, Wei WQ. Epidemiology of esophageal squamous cell carcinoma. Gastroenterology. 2018;154:360–73. https://doi.org/10.1053/j.gastro.2017.08.023.CrossRefPubMed

Stahl M, Mariette C, Haustermans K, Cervantes A, Arnold D. Oesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):51–6. https://doi.org/10.1093/annonc/mdt342.CrossRef

Liu Y, Ren Z, Yuan L, Xu S, Yao Z, Qiao L, Li K. Paclitaxel plus cisplatin vs. 5-fluorouracil plus cisplatin as first-line treatment for patients with advanced squamous cell esophageal cancer. Am J Cancer Res. 2016;6:2345–50.PubMedPubMedCentral

Popovic D, Vucic D, Dikic I. Ubiquitination in disease pathogenesis and treatment. Nat Med. 2014;20:1242–53. https://doi.org/10.1038/nm.3739.CrossRefPubMed

Salas-Lloret D, González-Prieto R. Insights in post-translational modifications: ubiquitin and SUMO. Int J Mol Sci. 2022. https://doi.org/10.3390/ijms23063281].CrossRefPubMedPubMedCentral

Nijman SM, Luna-Vargas MP, Velds A, Brummelkamp TR, Dirac AM, Sixma TK, Bernards R. A genomic and functional inventory of deubiquitinating enzymes. Cell. 2005;123:773–86. https://doi.org/10.1016/j.cell.2005.11.007.CrossRefPubMed

Li Y, Reverter D. Molecular mechanisms of DUBs regulation in signaling and disease. Int J Mol Sci. 2022. https://doi.org/10.3390/ijms22030986].CrossRefPubMedPubMedCentral

Sharma A, Alswillah T, Singh K, Chatterjee P, Willard B, Venere M, Summers MK, Almasan A. USP14 regulates DNA damage repair by targeting RNF168-dependent ubiquitination. Autophagy. 2018;14:1976–90. https://doi.org/10.1080/15548627.2018.1496877.CrossRefPubMedPubMedCentral

Xu G, Yang Z, Ding Y, Liu Y, Zhang L, Wang B, Tang M, Jing T, Jiao K, Xu X, et al. The deubiquitinase USP16 functions as an oncogenic factor in K-RAS-driven lung tumorigenesis. Oncogene. 2021;40:5482–94. https://doi.org/10.1038/s41388-021-01964-6.CrossRefPubMed

10.

Li X, Song N, Liu L, Liu X, Ding X, Song X, Yang S, Shan L, Zhou X, Su D, et al. USP9X regulates centrosome duplication and promotes breast carcinogenesis. Nat Commun. 2017;8:14866. https://doi.org/10.1038/ncomms14866.CrossRefPubMedCentral

11.

Soncini C, Berdo I, Draetta G. Ras-GAP SH3 domain binding protein (G3BP) is a modulator of USP10, a novel human ubiquitin specific protease. Oncogene. 2001;20:3869–79. https://doi.org/10.1038/sj.onc.1204553.CrossRefPubMed

12.

Yuan J, Luo K, Zhang L, Cheville JC, Lou Z. USP10 regulates p53 localization and stability by deubiquitinating p53. Cell. 2010;140:384–96. https://doi.org/10.1016/j.cell.2009.12.032.CrossRefPubMedPubMedCentral

13.

Jochemsen AG, Shiloh Y. USP10: friend and foe. Cell. 2010;140:308–10. https://doi.org/10.1016/j.cell.2010.01.034.CrossRef

14.

Bhattacharya U, Neizer-Ashun F, Mukherjee P, Bhattacharya R. When the chains do not break: the role of USP10 in physiology and pathology. Cell Death Dis. 2020;11:1033. https://doi.org/10.1038/s41419-020-03246-7.CrossRefPubMedPubMedCentral

15.

Weisberg EL, Schauer NJ, Yang J, Lamberto I, Doherty L, Bhatt S, Nonami A, Meng C, Letai A, Wright R, et al. Inhibition of USP10 induces degradation of oncogenic FLT3. Nat Chem Biol. 2017;13:1207–15. https://doi.org/10.1038/nchembio.2486.CrossRefPubMedPubMedCentral

16.

Mannaerts I, Leite SB, Verhulst S, Claerhout S, Eysackers N, Thoen LF, Hoorens A, Reynaert H, Halder G, van Grunsven LA. The Hippo pathway effector YAP controls mouse hepatic stellate cell activation. J Hepatol. 2015;63:679–88. https://doi.org/10.1016/j.jhep.2015.04.011.CrossRefPubMed

17.

Meng Z, Moroishi T, Guan KL. Mechanisms of Hippo pathway regulation. Genes Dev. 2016;30:1–17. https://doi.org/10.1101/gad.274027.115.CrossRefPubMedPubMedCentral

18.

Song J, Wang T, Chi X, Wei X, Xu S, Yu M, He H, Ma J, Li X, Du J, et al. Kindlin-2 inhibits the hippo signaling pathway by promoting degradation of MOB1. Cell Rep. 2019;29:3664-77.e3665. https://doi.org/10.1016/j.celrep.2019.11.035.CrossRefPubMed

19.

Ma S, Meng Z, Chen R, Guan KL. The hippo pathway: biology and pathophysiology. Annu Rev Biochem. 2019;88:577–604. https://doi.org/10.1146/annurev-biochem-013118-111829.CrossRefPubMed

20.

Kofler M, Speight P, Little D, Di Ciano-Oliveira C, Szászi K, Kapus A. Mediated nuclear import and export of TAZ and the underlying molecular requirements. Nat Commun. 2018;9:4966. https://doi.org/10.1038/s41467-018-07450-0.CrossRefPubMedPubMedCentral

21.

Zhang J, Zhou Y, Tang PMK, Cheng ASL, Yu J, To KF, Kang W. Mechanotransduction and cytoskeleton remodeling shaping YAP1 in gastric tumorigenesis. Int J Mol Sci. 2019. https://doi.org/10.3390/ijms20071576].CrossRefPubMedPubMedCentral

22.

Sabra H, Brunner M, Mandati V, Wehrle-Haller B, Lallemand D, Ribba AS, Chevalier G, Guardiola P, Block MR, Bouvard D. β1 integrin-dependent Rac/group I PAK signaling mediates YAP activation of Yes-associated protein 1 (YAP1) via NF2/merlin. J Biol Chem. 2017;292:19179–97. https://doi.org/10.1074/jbc.M117.808063.CrossRefPubMedPubMedCentral

23.

Hou S, Jin W, Xiao W, Deng B, Wu D, Zhi J, Wu K, Cao X, Chen S, Ding Y, et al. Integrin α5 promotes migration and cisplatin resistance in esophageal squamous cell carcinoma cells. Am J Cancer Res. 2019;9:2774–88.PubMedPubMedCentral

24.

Hou S, Hao X, Li J, Weng S, Wang J, Zhao T, Li W, Hu X, Deng B, Gu J, et al. TM4SF1 promotes esophageal squamous cell carcinoma metastasis by interacting with integrin α6. Cell Death Dis. 2022;13:609. https://doi.org/10.1038/s41419-022-05067-2.CrossRefPubMedCentral

25.

Hou S, Hang Q, Isaji T, Lu J, Fukuda T, Gu J. Importance of membrane-proximal N-glycosylation on integrin β1 in its activation and complex formation. FASEB J. 2016;30:4120–31. https://doi.org/10.1096/fj.201600665R.CrossRefPubMed

26.

Hang Q, Isaji T, Hou S, Im S, Fukuda T, Gu J. Integrin α5 suppresses the phosphorylation of epidermal growth factor receptor and its cellular signaling of cell proliferation via N-glycosylation. J Biol Chem. 2015;290:29345–60. https://doi.org/10.1074/jbc.M115.682229.CrossRefPubMedPubMedCentral

27.

Hang Q, Zeng L, Wang L, Nie L, Yao F, Teng H, Deng Y, Yap S, Sun Y, Frank SJ, et al. Non-canonical function of DGCR8 in DNA double-strand break repair signaling and tumor radioresistance. Nat Commun. 2021;12:4033. https://doi.org/10.1038/s41467-021-24298-z.CrossRefPubMedCentral

28.

You BH, Yoon JH, Kang H, Lee EK, Lee SK, Nam JW. HERES, a lncRNA that regulates canonical and noncanonical Wnt signaling pathways via interaction with EZH2. Proc Natl Acad Sci U S A. 2019;116:24620–9. https://doi.org/10.1073/pnas.1912126116.CrossRefPubMedPubMedCentral

29.

Chen SW, Zhou HF, Zhang HJ, He RQ, Huang ZG, Dang YW, Yang X, Liu J, Fu ZW, Mo JX, et al. The clinical significance and potential molecular mechanism of PTTG1 in Esophageal squamous cell carcinoma. Front Genet. 2020;11: 583085. https://doi.org/10.3389/fgene.2020.583085.CrossRefPubMed

30.

Wang W, Wei C, Li P, Wang L, Li W, Chen K, Zhang J, Zhang W, Jiang G. Integrative analysis of mRNA and lncRNA profiles identified pathogenetic lncRNAs in esophageal squamous cell carcinoma. Gene. 2018;661:169–75. https://doi.org/10.1016/j.gene.2018.03.066.CrossRefPubMed

31.

Zhu H, Yan F, Yuan T, Qian M, Zhou T, Dai X, Cao J, Ying M, Dong X, He Q, et al. USP10 promotes proliferation of hepatocellular carcinoma by deubiquitinating and stabilizing YAP/TAZ. Cancer Res. 2020;80:2204–16. https://doi.org/10.1158/0008-5472.can-19-2388.CrossRef

32.

Takayama KI, Suzuki T, Fujimura T, Takahashi S, Inoue S. Association of USP10 with G3BP2 inhibits p53 signaling and contributes to poor outcome in prostate cancer. Mol Cancer Res. 2018;16:846–56. https://doi.org/10.1158/1541-7786.mcr-17-0471.CrossRefPubMed

33.

Chen Q, Hang Y, Zhang T, Tan L, Li S, Jin Y. USP10 promotes proliferation and migration and inhibits apoptosis of endometrial stromal cells in endometriosis through activating the Raf-1/MEK/ERK pathway. Am J Physiol Cell Physiol. 2018;315:C863-c872. https://doi.org/10.1152/ajpcell.00272.2018.CrossRef

34.

Zanconato F, Cordenonsi M, Piccolo S. YAP/TAZ at the roots of cancer. Cancer Cell. 2016;29:783–803. https://doi.org/10.1016/j.ccell.2016.05.005.CrossRefPubMedPubMedCentral

35.

Yuan T, Chen Z, Yan F, Qian M, Luo H, Ye S, Cao J, Ying M, Dai X, Gai R, et al. Deubiquitinating enzyme USP10 promotes hepatocellular carcinoma metastasis through deubiquitinating and stabilizing Smad4 protein. Mol Oncol. 2020;14:197–210. https://doi.org/10.1002/1878-0261.12596.CrossRefPubMed

36.

Sun T, Xu YJ, Jiang SY, Xu Z, Cao BY, Sethi G, Zeng YY, Kong Y, Mao XL. Suppression of the USP10/CCND1 axis induces glioblastoma cell apoptosis. Acta Pharmacol Sin. 2021;42:1338–46. https://doi.org/10.1038/s41401-020-00551-x.CrossRefPubMed

37.

Lin Z, Yang H, Tan C, Li J, Liu Z, Quan Q, Kong S, Ye J, Gao B, Fang D. USP10 antagonizes c-Myc transcriptional activation through SIRT6 stabilization to suppress tumor formation. Cell Rep. 2013;5:1639–49. https://doi.org/10.1016/j.celrep.2013.11.029.CrossRefPubMedPubMedCentral

38.

Kim K, Huh T, Park Y, Koo DH, Kim H, Hwang I, Choi CH, Yi JM, Chung JY. Prognostic significance of USP10 and p14ARF expression in patients with colorectal cancer. Pathol Res Pract. 2020;216: 152988. https://doi.org/10.1016/j.prp.2020.152988.CrossRefPubMed

39.

Sun J, Li T, Zhao Y, Huang L, Sun H, Wu H, Jiang X. USP10 inhibits lung cancer cell growth and invasion by upregulating PTEN. Mol Cell Biochem. 2018;441:1–7. https://doi.org/10.1007/s11010-017-3170-2.CrossRefPubMed

40.

Zeng Z, Wu HX, Zhan N, Huang YB, Wang ZS, Yang GF, Wang P, Fu GH. Prognostic significance of USP10 as a tumor-associated marker in gastric carcinoma. Tumour Biol. 2014;35:3845–53. https://doi.org/10.1007/s13277-013-1509-1.CrossRefPubMed

41.

Nakajima M, Kato H. Treatment options for esophageal squamous cell carcinoma. Expert Opin Pharmacother. 2013;14:1345–54. https://doi.org/10.1517/14656566.2013.801454.CrossRefPubMed

42.

Zeng Z, Li D, Yu T, Huang Y, Yan H, Gu L, Yuan J. Association and clinical implication of the USP10 and MSH2 proteins in non-small cell lung cancer. Oncol Lett. 2019;17:1128–38. https://doi.org/10.3892/ol.2018.9702.CrossRefPubMed

43.

Liu J, Xia H, Kim M, Xu L, Li Y, Zhang L, Cai Y, Norberg HV, Zhang T, Furuya T, et al. Beclin1 controls the levels of p53 by regulating the deubiquitination activity of USP10 and USP13. Cell. 2011;147:223–34. https://doi.org/10.1016/j.cell.2011.08.037.CrossRefPubMedPubMedCentral

44.

Guo J, Zhang J, Liang L, Liu N, Qi M, Zhao S, Su J, Liu J, Peng C, Chen X, et al. Potent USP10/13 antagonist spautin-1 suppresses melanoma growth via ROS-mediated DNA damage and exhibits synergy with cisplatin. J Cell Mol Med. 2020;24:4324–40. https://doi.org/10.1111/jcmm.15093.CrossRefPubMedCentral

45.

Liao Y, Guo Z, Xia X, Liu Y, Huang C, Jiang L, Wang X, Liu J, Huang H. Inhibition of EGFR signaling with Spautin-1 represents a novel therapeutics for prostate cancer. J Exp Clin Cancer Res. 2019;38:157. https://doi.org/10.1186/s13046-019-1165-4.CrossRefPubMedPubMedCentral

46.

Fan YH, Cheng J, Vasudevan SA, Dou J, Zhang H, Patel RH, Ma IT, Rojas Y, Zhao Y, Yu Y, et al. USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis. Cell Death Dis. 2013;4: e867. https://doi.org/10.1038/cddis.2013.400.CrossRefPubMedPubMedCentral

47.

Mooring M, Fowl BH, Lum SZC, Liu Y, Yao K, Softic S, Kirchner R, Bernstein A, Singhi AD, Jay DG, et al. Hepatocyte stress increases expression of yes-associated protein and transcriptional coactivator with PDZ-binding motif in hepatocytes to promote parenchymal inflammation and fibrosis. Hepatology. 2020;71:1813–30. https://doi.org/10.1002/hep.30928.CrossRefPubMed

48.

Guan H, Shang G, Cui Y, Liu J, Sun X, Cao W, Wang Y, Li Y. Long noncoding RNA APTR contributes to osteosarcoma progression through repression of miR-132-3p and upregulation of yes-associated protein 1. J Cell Physiol. 2019;234:8998–9007. https://doi.org/10.1002/jcp.27572.CrossRefPubMed

49.

Fan YP, Liao JZ, Lu YQ, Tian DA, Ye F, Zhao PX, Xiang GY, Tang WX, He XX. MiR-375 and doxorubicin co-delivered by liposomes for combination therapy of hepatocellular carcinoma. Mol Ther Nucleic acids. 2017;7:181–9. https://doi.org/10.1016/j.omtn.2017.03.010.CrossRefPubMedPubMedCentral

50.

Qadir J, Riaz SK, Taj K, Sattar N, Sahar NE, Khan JS, Kayani MA, Haq F, Arshad Malik MF. Increased YAP1 expression is significantly associated with breast cancer progression, metastasis and poor survival. Future Oncol. 2021;17:2725–34. https://doi.org/10.2217/fon-2020-1080.CrossRefPubMed

51.

Zhang Z, Du J, Wang S, Shao L, Jin K, Li F, Wei B, Ding W, Fu P, van Dam H, et al. OTUB2 promotes cancer metastasis via hippo-independent activation of YAP and TAZ. Mol Cell. 2019;73:7-21.e27. https://doi.org/10.1016/j.molcel.2018.10.030.CrossRefPubMed

52.

Yi X, Deng X, Zhao Y, Deng B, Deng J, Fan H, Du Y, Hao L. Ubiquitin-like protein FAT10 promotes osteosarcoma growth by modifying the ubiquitination and degradation of YAP1. Exp Cell Res. 2020;387: 111804. https://doi.org/10.1016/j.yexcr.2019.111804.CrossRefPubMed

53.

Gao Y, Zhang X, Xiao L, Zhai C, Yi T, Wang G, Wang E, Ji X, Hu L, Shen G, et al. Usp10 modulates the hippo pathway by deubiquitinating and stabilizing the transcriptional Coactivator Yorkie. Int J Mol Sci. 2019. https://doi.org/10.3390/ijms20236013].CrossRefPubMedPubMedCentral

54.

Qiu Y, Huang D, Sheng Y, Huang J, Li N, Zhang S, Hong Z, Yin X, Yan J. Deubiquitinating enzyme USP46 suppresses the progression of hepatocellular carcinoma by stabilizing MST1. Exp Cell Res. 2021;405: 112646. https://doi.org/10.1016/j.yexcr.2021.112646.CrossRefPubMed

55.

Kim JY, Lee DM, Woo HG, Kim KD, Lee HJ, Kwon YJ, Choi KS. RNAi screening-based identification of USP10 as a novel regulator of paraptosis. Sci Rep. 2019;9:4909. https://doi.org/10.1038/s41598-019-40982-z.CrossRefPubMedPubMedCentral

Titel: USP10 promotes migration and cisplatin resistance in esophageal squamous cell carcinoma cells
verfasst von: Sicong Hou
Tiantian Zhao
Bin Deng
Caimin Li
Wenqian Li
Haifeng Huang
Qinglei Hang
Publikationsdatum: 01.01.2024
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 1/2024
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-023-02272-7

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

USP10 promotes migration and cisplatin resistance in esophageal squamous cell carcinoma cells

Abstract

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2024

Synergistic anti-proliferative and apoptotic effect of NVP-BEZ235 and curcumin on human SH-SY5Y neuroblastoma cells

Inhibition of PI3K-AKT-mTOR pathway and modulation of histone deacetylase enzymes reduce the growth of acute myeloid leukemia cells

In silico study of polyphenols as potential inhibitors of MALT1 protein in non-Hodgkin lymphoma

Chitosan-encapsulated naringenin promotes ROS mediated through the activation of executioner caspase-3

Oncolytic viruses improve cancer immunotherapy by reprogramming solid tumor microenvironment

Epithelial to mesenchymal transition (EMT) in metaplastic breast cancer and phyllodes breast tumors

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie